PepDose blogs

How many units is 2.5 mg?

Units = mg ÷ mg per mL × 100 on a U-100 syringe. Charts for 10, 20 and 30 mg vials with 1, 2 or 3 mL of bacteriostatic water.

Arithmetic, with a calculator

Semaglutide vs tirzepatide

In SURMOUNT-5, the one head-to-head obesity trial, average weight change over 72 weeks was −20.2% on tirzepatide and −13.7% on semaglutide. Semaglutide acts on the GLP-1 receptor; tirzepatide acts on GIP and GLP-1. Both are FDA-approved, and semaglutide also has a large heart-outcome trial (SELECT).

Includes a head-to-head trial

Tirzepatide vs retatrutide

Tirzepatide acts on two receptors (GIP and GLP-1) and is FDA-approved. Retatrutide adds a third, glucagon, and is not approved. In separate trials, top-dose weight change was −20.9% at 72 weeks on tirzepatide 15 mg (SURMOUNT-1) and −25.0% at 80 weeks on retatrutide 12 mg (TRIUMPH-1). No head-to-head trial exists.

Separate trials, no head-to-head

Semaglutide vs retatrutide

Retatrutide acts on three receptors (GIP, GLP-1 and glucagon) and is not FDA-approved. Semaglutide, sold as Wegovy and Ozempic, acts on one (GLP-1) and is approved. In separate trials, weight change was −25.0% at 80 weeks on retatrutide 12 mg (TRIUMPH-1) and −14.9% at 68 weeks on semaglutide 2.4 mg (STEP 1). No head-to-head trial exists.

Separate trials, no head-to-head

Weight-loss peptides compared

Three once-weekly peptides have large obesity trials. Semaglutide (GLP-1) showed −14.9% average weight change, tirzepatide (GIP and GLP-1) −20.9%, and retatrutide (GIP, GLP-1 and glucagon) −25.0% on their top doses. Semaglutide and tirzepatide are FDA-approved; retatrutide is not. Only semaglutide and tirzepatide have been compared head to head.

Separate trials, no head-to-head

BPC-157 vs TB-500

Both are unapproved peptides studied mainly in animals for tissue healing. BPC-157 is a fragment of a gastric-juice protein; TB-500 is a synthetic relative of thymosin beta-4, which helps cells move into injured tissue. BPC-157 has a few small human reports. For TB-500, the FDA identified no human exposure data.

Separate trials, no head-to-head

Tesamorelin vs CJC-1295 + ipamorelin

All three raise the body's own growth hormone. Tesamorelin is an FDA-approved GHRH analog with phase 3 trials in more than 800 people, where it cut visceral fat by about 15%. CJC-1295 and ipamorelin are not approved; their human data is limited to small early studies, and ipamorelin remains on the FDA's compounding safety-risk list.

Separate trials, no head-to-head

GLOW vs KLOW

The difference is one peptide: KLOW is GLOW plus KPV. GLOW usually holds GHK-Cu, BPC-157 and TB-500 in a 70 mg vial; KLOW adds 10 mg of KPV in an 80 mg vial. Neither blend has been studied as a combination, and no component is an FDA-approved drug.

Separate trials, no head-to-head